GLUCAGON

Peak

glucagon

NDAINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSPOWDER
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

stomach, small bowel, and colon.

Clinical Trials (5)

NCT07246421N/ARecruiting

Glucagon Resistance in Patients With MASLD and T2DM

Started Jan 2026
24 enrolled
Metabolic Associated Fatty Liver DiseaseType 2 Diabetes (T2DM)
NCT05202353Phase 1Recruiting

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Started Oct 2024
30 enrolled
Obesity
NCT05663515N/ARecruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

Started Sep 2024
24,000 enrolled
Pancreatic Cancer
NCT06588504Phase 1Completed

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Started Sep 2024
38 enrolled
Diabetes Mellitus, Type 1
NCT05751720Phase 1/2Unknown

Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

Started Oct 2023
30 enrolled
Non-Alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisType 2 Diabetes+1 more